Sionna Therapeutics (SION) Reiterated at Market Perform by Citizens Amid Ph2a Trial Issues
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Perform rating on Sionna Therapeutics (NASDAQ: SION).The analyst commented, "New analysis of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




